M 2001

Drug Profile

M 2001

Alternative Names: M-2001

Latest Information Update: 25 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SyndromeX
  • Class
  • Mechanism of Action AMP activated protein kinase modulators; FOXO1 protein expression modulators; Hepatocyte nuclear factor 4 modulators; Mitochondrial permeability transition pore modulators; STAT3 transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 25 Jul 2016 Preclinical trials in Metabolic syndrome in Israel (PO)
  • 25 Jul 2016 Preclinical trials in Type-2 diabetes mellitus in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top